May 15, 2018
Cipher Pharmaceuticals Completes Acquisition of Canadian Business Portfolio of Cardiome Pharma
May 15, 2018
Correvio Pharma Corp Completes Strategic Transaction with Cipher Pharmaceuticals
May 10, 2018
Cardiome Announces Results From Annual and Special Meeting of Shareholders and Timing For First Quarter 2018 Financial Results Conference Call
Apr 26, 2018
Cardiome to Present at the Bloom Burton & Co. Healthcare Investor Conference
Apr 17, 2018
Cardiome Completes Enrollment in the Post Approval Safety Study SPECTRUM Evaluating Brinavess®
Apr 12, 2018
Cardiome Announces Fifteen Xydalba(TM) and Zevtera® Abstracts at ECCMID 2018
Apr 06, 2018
Cardiome Announces Amendment to Term Loan Agreement with CRG-Managed Funds
Apr 02, 2018
Cardiome Highlights Partner SteadyMed's Progress Towards Trevyent NDA Resubmission
Mar 28, 2018
Cardiome Announces Recent Insider Purchases
Mar 22, 2018
Health Canada Accepts Cardiome's Xydalba New Drug Submission and Grants Priority Review
Mar 20, 2018
Cipher Pharmaceuticals and Cardiome Pharma Announce Strategic Transaction for Canadian Business Portfolio of Cardiome
Mar 13, 2018
Cardiome Reports Fourth Quarter and Full Year 2017 Financial Results
Mar 06, 2018
Cardiome to Hold Fourth Quarter and Full Year 2017 Financial Results Conference Call on March 13
Feb 08, 2018
Cardiome to Present at the Leerink Partners 7th Annual Global Healthcare Conference
Jan 23, 2018
Cardiome Announces Expanded Label for Aggrastat® in China Including New STEMI Indication and High Dose Bolus Regimen
Jan 10, 2018
Cardiome to Participate in the Cantor Fitzgerald Antibiotics Summit
Dec 12, 2017
Cardiome Announces Strategic Licensing Agreement To Commercialize Aggrastat In Russia
Dec 11, 2017
Cardiome Highlights Partner SteadyMed's Agreement With FDA On Pathway To Trevyent NDA Resubmission
Dec 11, 2017
Cardiome Announces Xydalba(TM) Treatment And Patient Experience Presentations At The 2017 National Opat Conference
Nov 20, 2017
Cardiome to Present at the 29th Annual Piper Jaffray Healthcare Conference